Risk of Preterm Delivery and Growth Restriction in Spontaneous and Selective Fetal Reduction after IVF-ET

2005 ◽  
Vol 83 (5) ◽  
pp. S12
Author(s):  
M. Mitwally ◽  
H. Albuarki ◽  
M.H. Fakih ◽  
F.N. Shamma ◽  
J. Ayers ◽  
...  
2016 ◽  
Vol 127 ◽  
pp. 64S
Author(s):  
Mohamed Satti ◽  
Sina Abhari ◽  
Omar Abuzeid ◽  
Frederico G. Rocha ◽  
Ivana Vettraino ◽  
...  

2021 ◽  
Vol 29 (1) ◽  
pp. 36
Author(s):  
Fita Maulina ◽  
M Adya F F Dilmy ◽  
Ali Sungkar

Objectives: To report maternal and perinatal outcomes of hyperthyroidsm in pregnancy.Case Report: There were 3622 cases of delivering pregnant women during the period of the study. From this number, the prevalence of pregnant women with hyperthyroid was 0.2 %. We reported 9 cases of hyperthyroid in pregnancy. The number of pregnancy complication and outcome on pregnant women with hyperthyroidism were preterm labor (44%) and preeclampsia (22%), both were found in group of mother who did taking antihyperthyroid therapy. In those who did not take antihyperthyroid therapy 11% had spontaneous abortion and 11% had preterm delivery. Fetal complications were intrauterine growth restriction (11%) and intrauterine fetal death (23%), both of these complication were on the group who did not take antihyperthyroid. On the contrary, 44% babies were born with normal birthweight in group who took antihyperthyroid.Conclusion: There were differences noted between the group that took adequate treatment and the group that did not take antihyperthyroid. The incidence of intrauterine growth restriction and intrauterine fetal death were high in group that did not took antihyperthyroid therapy but the incidence of preterm delivery as the maternal complication was high in group that did take the antihyperthyroid therapy.  


2020 ◽  
Author(s):  
Shiri Shinar ◽  
Swati Agrawal ◽  
Darine El‐Chaâr ◽  
Nimrah Abbasi ◽  
Robert Beecroft ◽  
...  

2000 ◽  
Vol 164 (1) ◽  
pp. 7-11 ◽  
Author(s):  
O Ogueh ◽  
AP Hawkins ◽  
A Abbas ◽  
GD Carter ◽  
KH Nicolaides ◽  
...  

The aim of the study was to investigate maternal thyroid function in pregnancy by monitoring the circulating concentrations of thyroid stimulating hormone (TSH), free thyroxine (fT(4)) and human chorionic gonadotrophin (hCG) in multifetal pregnancies before and after embryo reduction. We studied two groups of women: group 1 comprised singleton (n=12) and twin (n=12) pregnancies achieved after superovulation and in vitro fertilisation and embryo transfer (IVF-ET), and group 2 were multifetal pregnancies (n=39) undergoing selective fetal reduction to twin pregnancies. Blood samples were obtained initially at 10-12 weeks gestation (before fetal reduction) and then 4 and 8 weeks afterwards. Before fetal reduction, the circulating concentrations of fT(4) in multifetal pregnancies were significantly greater than those in singleton or twin pregnancies (singleton, mean 16.49 pmol/l (interquartile range 14.09-18.13 pmol/l); twins, 15.84 (15.36-16.95 pmol/l); multifetal, 21.08 (16. 64-26.29 pmol/l); P<0.005 for singleton and twins), and in a multiple regression analysis, fT(4) was significantly related to the number of fetuses (F=23.739, P=0.0001), but not to hCG. After fetal reduction to twins, the circulating concentrations of fT(4) in multifetal pregnancies decreased progressively towards those in control twin pregnancies, but remained significantly greater at both 4 (P=0.003) and 8 weeks (P=0.050). This pattern of change in the concentrations of fT(4) is similar to, but lags behind, that of hCG, which attains twin levels 4 weeks after fetal reduction. This may represent a delayed thyroid response to the decreasing concentrations of hCG, but the alternative is that the maternal thyroid function is controlled by a fetal factor in addition to hCG.


Author(s):  
Vatsla Dadhwal ◽  
Aparna K. Sharma ◽  
Dipika Deka ◽  
Latika Chawla ◽  
Nutan Agarwal

Sign in / Sign up

Export Citation Format

Share Document